Published in:
01-07-2020 | Acute Respiratory Distress-Syndrome | Original Article
Clinical course of COVID-19 in patients with pre-existing decompensated cirrhosis: initial report from China
Published in: Hepatology International | Issue 4/2020
Login to get accessAbstract
Background
The clinical characteristics and disease course in COVID-19 patients with pre-existing decompensated cirrhosis has not been described so far.
Methods
In this case series, we report three patients with confirmed COVID-19 and pre-existing decompensated cirrhosis from three hospitals in Hubei, the epicenter of the outbreak in China.
Result
Patient 1 was a 53-year-old man with hepatitis B virus-related cirrhosis, portal hypertension, and ascites. Though receiving intensive support, he died of irreversible multiple organ dysfunction syndrome 48 days after the onset of the illness. Patient 2 was a 75-year-old woman with a history of schistosomiasis-related cirrhosis, portal hypertension, and ascites. Her family members requested that invasive rescue measures not be undertaken, and she died of acute respiratory distress syndrome 40 days after presenting with COVID-19 infection. Patient 3 was an 87-year-old man with alcohol-related cirrhosis, portal hypertension, and esophageal variceal hemorrhage. He was discharged from the hospital 29 days after illness onset.
Conclusion
The case series raise the possibility that decompensated cirrhosis may be a risk factor for a poor outcome in patients with COVID-19.